These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19030742)

  • 1. Clinical and biochemical evaluation of HIV-related lipodystrophy in an ambulatory population from the Hospital Universitário Cassiano Antonio de Morais, Vitória, ES, Brazil.
    Monnerat BZ; Cerutti Junior C; Caniçali SC; Motta TR
    Braz J Infect Dis; 2008 Aug; 12(4):364-8. PubMed ID: 19030742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipodystrophy in children and adolescents with acquired immunodeficiency syndrome and its relationship with the antiretroviral therapy employed.
    Sarni RO; Souza FI; Battistini TR; Pitta TS; Fernandes AP; Tardini PC; Fonseca FL; Dos Santos VP; Lopez FA
    J Pediatr (Rio J); 2009; 85(4):329-34. PubMed ID: 19668909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
    Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
    Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoadiponectinemia, dyslipidemia, and impaired growth in children with HIV-associated facial lipoatrophy.
    Kim RJ; Carlow DC; Rutstein JH; Rutstein RM
    J Pediatr Endocrinol Metab; 2007 Jan; 20(1):65-74. PubMed ID: 17315531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of highly active antiretroviral therapy (HAART) on cholesterol in HIV-1 infected children: a retrospective cohort study.
    Kim JY; Zaoutis T; Chu J; Zhao H; Rutstein R
    Pharmacoepidemiol Drug Saf; 2009 Jul; 18(7):589-94. PubMed ID: 19402031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of HIV infection and HAART on serum lipids in men.
    Riddler SA; Smit E; Cole SR; Li R; Chmiel JS; Dobs A; Palella F; Visscher B; Evans R; Kingsley LA
    JAMA; 2003 Jun; 289(22):2978-82. PubMed ID: 12799406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with lipodystrophy.
    Shah M; Tierney K; Adams-Huet B; Boonyavarakul A; Jacob K; Quittner C; Dinges W; Peterson D; Garg A
    HIV Med; 2005 Jul; 6(4):291-8. PubMed ID: 16011535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy.
    Sutinen J; Korsheninnikova E; Funahashi T; Matsuzawa Y; Nyman T; Yki-Järvinen H
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1907-10. PubMed ID: 12679491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].
    Streinu-Cercel A; Ion DA; Chivu LI; Chivu RD
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):521-5. PubMed ID: 17571539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Aurpibul L; Puthanakit T; Lee B; Mangklabruks A; Sirisanthana T; Sirisanthana V
    Antivir Ther; 2007; 12(8):1247-54. PubMed ID: 18240864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipodystrophy in HIV/AIDS patients with different levels of physical activity while on antiretroviral therapy.
    Segatto AF; Freitas Junior IF; Santos VR; Alves KC; Barbosa DA; Portelinha Filho AM; Monteiro HL
    Rev Soc Bras Med Trop; 2011; 44(4):420-4. PubMed ID: 21860886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dyslipidemia in HIV Infected Children Receiving Highly Active Antiretroviral Therapy.
    Mandal A; Mukherjee A; Lakshmy R; Kabra SK; Lodha R
    Indian J Pediatr; 2016 Mar; 83(3):226-31. PubMed ID: 26334860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dyslipidemia in AIDS patients on highly active antiretroviral therapy.
    Nery MW; Martelli CM; Turchi MD
    Braz J Infect Dis; 2011; 15(2):151-5. PubMed ID: 21503402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral therapy-associated dyslipidemia in patients from a reference center in Brazil.
    Ceccato MG; Bonolo PF; Souza Neto AI; Araújo FS; Freitas MI
    Braz J Med Biol Res; 2011 Nov; 44(11):1177-83. PubMed ID: 22052375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy.
    Heath KV; Chan KJ; Singer J; O'Shaughnessy MV; Montaner JS; Hogg RS
    Int J Epidemiol; 2002 Oct; 31(5):1016-20. PubMed ID: 12435777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe dyslipidemia and immune activation in HIV patients with dysglycemia.
    Jin C; Ji S; Xie T; Höxtermann S; Fuchs W; Lu X; Wu H; Cheng L; Skaletz-Rorowski A; Brockmeyer NH; Wu N
    HIV Clin Trials; 2016 Sep; 17(5):189-96. PubMed ID: 27409415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.